Wegovy's sales ceiling piques interest in prelude to Novo Nordisk's second-quarter report
The Danish drugmaker’s current upper growth expectation is closer to hitting maximum production capacity after an guidance upgrade, an analyst says, anticipating the Q2 report on Thursday.
by marketwire, translated by kristoffer grønbæk & daniel pedersen
With preliminary growth figures and a significant upward adjustment of the 2023 guidance, Danish drugmaker Novo Nordisk has eliminated much of the suspense regarding the company’s second quarterly figures for the year, anticipated for release on Thursday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Analysts predict growth for Novo Nordisk thanks to Wegovy
For subscribers
